Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T20:09:04.002Z.
Calculation as of: 2026-10-06T20:09:04.002Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 69c6abe1898d62982c9f5472fcc208679ef9964d1dbc89e7ebe68f1e3eabf120
PE RATIO
N/A
Market Cap
$143.84M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | $143.60M | N/A | N/A | N/A | N/A |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $143.84M | N/A | N/A | N/A | N/A |
| Nyxoah S.A. (NYXH)vs › | $143.10M | N/A | N/A | N/A | N/A |
| Fortress Biotech, Inc. (FBIOP)vs › | $146.27M | 6.93 | 6.25 | 6.25 | 6.25 |
| Codexis, Inc. (CDXS)vs › | $146.28M | N/A | N/A | N/A | N/A |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.62M | N/A | N/A | N/A | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $146.67M | N/A | N/A | N/A | N/A |
| Sutro Biopharma, Inc. (STRO)vs › | $139.84M | N/A | N/A | N/A | N/A |
| Alpha Cognition Inc (ACOG)vs › | $139.47M | N/A | N/A | N/A | N/A |
| Immuneering Corporation (IMRX)vs › | $139.04M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$2.56
Forward EPS (Est.)
$-1.39
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
